Panteleimon Bakirtzoglou

This dataset aimed to explore associations between pre-SARS-CoV-2 infection exercise and sports-related physical activity (PA) levels and disease severity, along with treatments administered following the most recent SARS-CoV-2 infection. A comprehensive analysis investigated the relationships between PA categories (“Inactive”, “Low PA”, “Moderate PA”, “High PA”), disease severity (“Sporadic”, “Episodic”, “Recurrent”, “Frequent”, “Persistent”), and treatments post-SARS-CoV-2 infection (“No treatment”, “Home remedies”, “Prescribed medication”, “Hospital admission”, “Intensive care unit admission”) within a sample population (n = 5829) from the Hellenic territory. Utilizing the Active-Q questionnaire, data were collected from February to March 2023, capturing PA habits, participant characteristics, medical history, vaccination status, and illness experiences. Findings revealed an independent relationship between preinfection PA levels and disease severity (χ2 = 9.097, df = 12, p = 0.695). Additionally, a statistical dependency emerged between PA levels and illness treatment categories (χ2 = 39.362, df = 12, p < 0.001), particularly linking inactive PA with home remedies treatment. These results highlight the potential influence of preinfection PA on disease severity and treatment choices following SARS-CoV-2 infection. The dataset offers valuable insights into the interplay between PA, disease outcomes, and treatment decisions, aiding future research in shaping targeted interventions and public health strategies related to COVID-19 management.

Pre-exercise mangiferin–quercetin may enhance athletic performance. This study investigated the effect of mangiferin–quercetin supplementation on high-level male basketball players during a basketball exercise simulation test (BEST) comprising 24 circuits of 30 s activities with various movement distances. The participants were divided into two groups (EXP = 19 and CON = 19) and given a placebo one hour before the BEST (PRE-condition). The following week, the EXP group received mangiferin–quercetin (84 mg/140 mg), while the CON group received a placebo (POST-condition) before the BEST in a double-blind, cross-over design. The mean heart rate (HR) and circuit and sprint times (CT and ST) during the BEST were measured, along with the capillary blood lactate levels (La−), the subjective rating of muscle soreness (RPMS), and the perceived exertion (RPE) during a resting state prior to and following the BEST. The results showed significant interactions for the mean CT (p = 0.013) and RPE (p = 0.004); a marginal interaction for La− (p = 0.054); and non-significant interactions for the mean HR, mean ST, and RPMS. Moreover, the EXP group had significantly lower values in the POST condition for the mean CT (18.17 ± 2.08 s) and RPE (12.42 ± 1.02) compared to the PRE condition (20.33 ± 1.96 s and 13.47 ± 1.22, respectively) and the POST condition of the CON group (20.31 ± 2.10 s and 13.32 ± 1.16, respectively) (p < 0.05). These findings highlight the potential of pre-game mangiferin–quercetin supplementation to enhance intermittent high-intensity efforts in sports such as basketball.